{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:03:11Z","timestamp":1790892191276,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Diabetes Invest"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims\/Introduction<\/jats:title><jats:p>This study aimed to investigate the effects of sodium\u2013glucose cotransporter\u20092 inhibitors (SGLT2i) on new prescriptions of drugs, including antihypertensives, antigout\/antihyperuricemics and antidyslipidemics, for the treatment of lifestyle\u2010related diseases in Japanese patients with diabetes mellitus using the JMDC Claims Database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Patients with type\u20092 diabetes mellitus who were newly treated with SGLT2i or other oral antidiabetic drugs and had not been prescribed any antihypertensives, antigout\/antihyperuricemics or antidyslipidemics for at least 1\u2009year were extracted from the database. Using propensity score calibration matching (1:1), we assessed the proportion of patients who started the aforementioned concomitant medications within 2\u2009years, and the risk ratio of SGLT2i to other antidiabetic medication groups was calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In 856,796 patients with diabetes mellitus, 734, 1,197 and 703 propensity score calibration\u2010matched patients in each group were analyzed for the prescription of antihypertensives, antigout\/antihyperuricemics and antidyslipidemics, respectively. The new prescriptions of antihypertensives and antigout\/antihyperuricemics were lower in the SGLT2i group than those in the other oral antidiabetic drug group (risk ratio 0.66 and 0.37, respectively), whereas those of antidyslipidemics were more common in the SGLT2i group (risk ratio 1.43).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>New prescriptions of antihypertensives or antigout\/antihyperuricemics were lower for patients taking SGLT2i than those taking other oral antidiabetic drugs, probably due to a reduction of blood pressure and uric acid levels by SGLT2i. The more frequent prescriptions of antidyslipidemics might partially reflect a moderate increase in low\u2010density lipoprotein cholesterol levels as a result of sodium\u2013glucose cotransporter\u20092 inhibition.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdi.13887","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T05:28:02Z","timestamp":1658294882000},"page":"1842-1851","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effect of sodium\u2013glucose cotransporter\u20092 inhibitor medication on new prescriptions of antihypertensives, antigout\/antihyperuricemics and antidyslipidemics in Japan: Analysis using the <scp>JMDC<\/scp> Claims Database"],"prefix":"10.1111","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2722-5202","authenticated-orcid":false,"given":"Maki","family":"Gouda","sequence":"first","affiliation":[{"name":"Data Science Department, Ikuyaku. Integrated Value Development Division Mitsubishi Tanabe Pharma Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9900-9491","authenticated-orcid":false,"given":"Kenji","family":"Arakawa","sequence":"additional","affiliation":[{"name":"Medical Intelligence Department, Ikuyaku. Integrated Value Development Division Mitsubishi Tanabe Pharma Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Data Science Department, Ikuyaku. Integrated Value Development Division Mitsubishi Tanabe Pharma Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiteru","family":"Ushirogawa","sequence":"additional","affiliation":[{"name":"Data Science Department, Ikuyaku. Integrated Value Development Division Mitsubishi Tanabe Pharma Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S233538"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0406-8"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.703389"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(99)70312-1"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.8.832"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601043340103"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.150722"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"e_1_2_7_13_1","unstructured":"JMDC Claims Database. Available from:https:\/\/www.jmdc.co.jp\/en\/jmdc\u2010claims\u2010database\/Accessed March 2 2022."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S317371"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.42010"},{"key":"e_1_2_7_17_1","first-page":"324","article-title":"Essence of the revised guideline for the management of hyperuricemia and gout","volume":"55","author":"Yamanaka H","year":"2012","journal-title":"Japan Med Assoc J"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-020-00439-5"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105108"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0255-8"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.07703"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000094221.86888.AE"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S111991"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.7326\/M19-2610"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30078-5"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14559"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13101"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2433"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.1909"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105068"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0007114515004699"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/129.11.2005"},{"key":"e_1_2_7_34_1","first-page":"1103","article-title":"Intermittent fasting during Ramadan causes a transient increase in total, LDL, and HDL cholesterols and hs\u2010CRP in ethnic obese adolescents","volume":"173","author":"Radhakishun N","year":"2014","journal-title":"Eur J Pediatr"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.2337\/db16-0049"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.118.311339"}],"container-title":["Journal of Diabetes Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.13887","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdi.13887","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.13887","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T12:29:20Z","timestamp":1692620960000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdi.13887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1111\/jdi.13887"],"URL":"https:\/\/doi.org\/10.1111\/jdi.13887","archive":["Portico"],"relation":{},"ISSN":["2040-1116","2040-1124"],"issn-type":[{"value":"2040-1116","type":"print"},{"value":"2040-1124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,4]]},"assertion":[{"value":"2022-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}